NL300391I2 - Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin - Google Patents

Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Info

Publication number
NL300391I2
NL300391I2 NL300391C NL300391C NL300391I2 NL 300391 I2 NL300391 I2 NL 300391I2 NL 300391 C NL300391 C NL 300391C NL 300391 C NL300391 C NL 300391C NL 300391 I2 NL300391 I2 NL 300391I2
Authority
NL
Netherlands
Prior art keywords
japanese encephalitis
weakened
vero cells
vaccine
virus adapted
Prior art date
Application number
NL300391C
Other languages
English (en)
Dutch (nl)
Other versions
NL300391I1 (nl
Original Assignee
Cheil Jedang Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp, Us Army filed Critical Cheil Jedang Corp
Publication of NL300391I1 publication Critical patent/NL300391I1/nl
Publication of NL300391I2 publication Critical patent/NL300391I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300391C 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin NL300391I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
NL300391I1 NL300391I1 (nl) 2009-08-03
NL300391I2 true NL300391I2 (nl) 2009-11-02

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300391C NL300391I2 (nl) 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Country Status (15)

Country Link
US (1) US6309650B1 (US06559137-20030506-C00021.png)
EP (2) EP1025209B1 (US06559137-20030506-C00021.png)
JP (1) JP4161017B2 (US06559137-20030506-C00021.png)
KR (1) KR100314404B1 (US06559137-20030506-C00021.png)
CN (1) CN1142271C (US06559137-20030506-C00021.png)
AU (1) AU748730B2 (US06559137-20030506-C00021.png)
CA (1) CA2301000C (US06559137-20030506-C00021.png)
DE (2) DE122009000037I2 (US06559137-20030506-C00021.png)
DK (2) DK1604685T3 (US06559137-20030506-C00021.png)
ES (2) ES2382946T3 (US06559137-20030506-C00021.png)
FR (1) FR09C0037I2 (US06559137-20030506-C00021.png)
MY (1) MY129773A (US06559137-20030506-C00021.png)
NL (1) NL300391I2 (US06559137-20030506-C00021.png)
NZ (1) NZ503522A (US06559137-20030506-C00021.png)
WO (1) WO1999011762A1 (US06559137-20030506-C00021.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
EP1057889B1 (en) * 1998-10-05 2009-04-22 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
DK1183332T3 (da) * 1999-04-22 2010-09-06 Us Agriculture Porcint Reproduktions- og Respirations Syndrom-vaccine baseret på isolere JA-142
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈-丁二烯-苯乙烯共聚物及其回收方法
ES2317517T5 (es) * 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
JP5580600B2 (ja) * 2007-12-26 2014-08-27 北里第一三共ワクチン株式会社 安定に長期間保存できる日本脳炎ワクチンの製法方法及び該ワクチンの用途
KR101507822B1 (ko) * 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
KR20120027381A (ko) * 2009-05-25 2012-03-21 파나세아 바이오테크 리미티드 일본뇌염 백신 및 그것의 제조 방법
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DE202012012768U1 (de) 2011-12-06 2014-01-21 Valneva Austria Gmbh Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen
CN105744952A (zh) * 2013-09-14 2016-07-06 巴拉特生物技术国际有限公司 病毒疫苗及其制备方法
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
ES2973267T3 (es) 2015-12-23 2024-06-19 Valneva Se Purificación de virus
AU2017207076B2 (en) 2016-01-15 2021-04-29 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
CN118662621A (zh) 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
AU2018375789B2 (en) 2017-11-30 2021-11-11 Takeda Vaccines, Inc. Method for inactivating Zika virus and related methods
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
WO2020045368A1 (ja) * 2018-08-27 2020-03-05 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬,ワクチンなどの評価方法
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
CA2301000A1 (en) 1999-03-11
KR19990023955A (ko) 1999-03-25
NL300391I1 (nl) 2009-08-03
DK1025209T3 (da) 2007-06-25
EP1604685B1 (en) 2012-02-22
ES2281929T3 (es) 2007-10-01
DE69837211T2 (de) 2007-12-06
EP1604685A2 (en) 2005-12-14
KR100314404B1 (ko) 2002-10-12
JP2001514844A (ja) 2001-09-18
FR09C0037I2 (fr) 2021-11-05
DK1604685T3 (da) 2012-06-18
AU9004798A (en) 1999-03-22
DE122009000037I2 (de) 2011-06-16
CN1142271C (zh) 2004-03-17
CA2301000C (en) 2003-07-08
EP1025209B1 (en) 2007-02-28
CN1272879A (zh) 2000-11-08
EP1025209A1 (en) 2000-08-09
EP1604685A3 (en) 2006-07-05
FR09C0037I1 (US06559137-20030506-C00021.png) 2009-09-25
MY129773A (en) 2007-04-30
NZ503522A (en) 2001-06-29
US6309650B1 (en) 2001-10-30
DE69837211D1 (de) 2007-04-12
ES2382946T3 (es) 2012-06-14
JP4161017B2 (ja) 2008-10-08
AU748730B2 (en) 2002-06-13
DE122009000037I1 (de) 2009-11-05
WO1999011762A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
NL300391I2 (nl) Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin
CY2012033I1 (el) Φαρμακευτικα σκευασματα σε μορφη αερολυματος
BR9609258A (pt) Vacinas contra hepatite c
PT810877E (pt) Vacina da hepatite b
DE69630044D1 (de) Viren inaktivierende umhüllungen
NO20003302D0 (no) Vaksine
DE122007000035I1 (de) 5-Alkyl-2-Arylaminophenylessigs{ure und derivative
DE60018074D1 (de) Faltbarer einweg-dosieraerosolabstandshalter und verfahren dazu
NO20004104L (no) Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater
ID22873A (id) Senyawa-senyawa heterosiklik dan pemakaiannya untuk menginhibisi b-amyloid peptida
HUP9800802A3 (en) Influenza vaccine
IT1317988B1 (it) Procedimento e dispositivo per produrre depressione in un veicolo
EP1037974A4 (en) TRUNCATED PROTEIN OF HEPATITIS C VIRUS NS5B AND RELATED METHODS OF IDENTIFYING ANTIVIRAL COMPOUNDS
FI950567A0 (fi) Hepatitis A-virusrokote
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
ATE277631T1 (de) Neospora impstoff
ATE262324T1 (de) Verkapslung einer untereinheit des bovinen herpes virus typ-1 in wässrigen lösungsmitteln als impfstoff.
GB9713979D0 (en) Method for attaching peg to macromolecules
ID26355A (id) Loop penggantung untuk sosis atau sejenisnya dan suatu metode untuk memproduksinya
HK1034202A1 (en) Combined vaccine against hepatitis a and hepatitisb
ATE240392T1 (de) Spezifische oligonukleotide fuer hepatitis c- virus
ID28381A (id) Vankoresmisin, suatu proses untuk memproduksinya dan penggunaanya sebagai obat-obatan
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
HU0400424D0 (en) Hepatitis virus vaccines
DE60024406D1 (de) Fischsosse und Verfahren zu deren Herstellung